Evidence map›Paper›PMID 29970059›Full record

Trial reportBMC musculoskeletal disorders2018

Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D

Er-Yuan Liao, Zhen-Lin Zhang, Wei-Bo Xia, Hua Lin, Qun Cheng, Li Wang, Yong-Qiang Hao, De-Cai Chen, Hai Tang, Yong-De Peng and 7 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC musculoskeletal disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions.International journal of molecular sciences · 2019
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 1 country.

Er-Yuan LiaoThe Second Xiangya Hospital, Central South University, Changsha, China.
Zhen-Lin ZhangThe Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Wei-Bo XiaDepartment of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Wangfujing, Dongcheng District, Beijing, 100730, China. xiaweibo8301@163.com.
Hua LinNanjing Drum Tower Hospital, Nanjing, China.
Qun ChengHuadong Hospital Affiliated to Fudan University, Shanghai, China.
Li WangTianjin Hospital, Tianjin, China.
Yong-Qiang HaoThe Ninth People's Hospital, Shanghai, China.
De-Cai ChenWest China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Hai TangBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Yong-De PengThe First People's Hospital, Shanghai, China.
Li YouThe First People's Hospital, Shanghai, China.
Liang HeBeijing Jishuitan Hospital, Beijing, China.
Zhao-Heng HuPeking University People's Hospital, Beijing, China.
Chun-Li SongPeking University Third Hospital, Beijing, China.
Fang WeiGlobal Medical Affairs, Merck Sharp & Dohme China, Shanghai, China.
Jue WangGlobal Medical Affairs, Merck Sharp & Dohme China, Shanghai, China.
Lei ZhangGlobal Medical Affairs, Merck Sharp & Dohme China, Shanghai, China.
Shanghai Medical Information Center · CNShanghai First People's Hospital · CNBeijing Friendship Hospital · CNCentral South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHuadong Hospital · CNNanjing Drum Tower Hospital · CNPeking University · CNPeking University People's Hospital · CNPeking University Third Hospital · CNShanghai Ninth People's Hospital · CNShanghai Sixth People's Hospital · CNSichuan University · CNTianjin Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitamin D (VD) insufficiency or deficiency is a frequent comorbidity in Chinese women with postmenopausal osteoporosis (PMO). The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of alendronate sodium and 5600 IU of vitamin D

methodsChinese PMO women (n = 219) were treated with 12-month ALN/D5600 (n = 111) or calcitriol (n = 108). Changes in 25(OH) D at month 12 were post hoc analyzed by the baseline 25 (OH) D status using the longitudinal analysis. The main safety outcome measures included serum calcium and phosphate and 24-h urine calcium, and the repeated measures mixed model was used to assess the frequencies of the calcium-phosphate metabolic disorders.

resultsAbsolute change in mean serum 25(OH) D level was the greatest in VD-deficient patients and least in VD-sufficient patients at months six and 12 (both, P < 0.01). Serum calcium level remained significantly lower in the ALN/D5600 treatment group than in the calcitriol treatment group throughout the 12 months. Mean 24-h urine calcium slightly increased in the ALN/D5600 treatment group and significantly increased in the calcitriol treatment group (+ 1.1 and + 0.9 mmol/L at months six and 12; both, P < 0.05). Calcitriol treatment was associated with more frequent hypercalciuria at month six (9.4% vs. 18.5%, P = 0.05), but not at month 12 (12.3% vs. 13.0%).

conclusionBaseline VD status predicted 25(OH) D improvement in PMO patients on 12-month ALN/D5600 treatment. The daily use of 0.25 μg of calcitriol was associated with more frequent hypercalciuria at month six, compared to ALN/5600 treatment, necessitating the safety re-evaluation of calcitriol at a higher dosage.

Indexed as

AgedAged, 80 and overAlendronateBiomarkersBone DensityBone Density Conservation AgentsCalcifediolCalcium PhosphatesChinaCholecalciferolFemaleHumansHypercalciuriaMiddle AgedOsteoporosis, PostmenopausalTreatment Outcome25-hydroxyvitamin DAlendronateBiomarkersBone Density Conservation AgentsCalcifediolcalcium phosphateCalcium PhosphatesCholecalciferolVitamin DAlendronate sodiumCalcifediolCalcitriolCalcium/phosphate metabolismPostmenopausal osteoporosis

Identifiers

PMID29970059
PMCPMC6030763
OpenAlexW2810206998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.